| 148 | |
| Summary | Gut microbes (species: Lactobacillus reuteri) decrease Rituximab's toxicity. |
| Gut | |
| Rituximab (PubChem CID: 46488338) | |
| Lactobacillus reuteri (Tax ID: 1598) | |
| 34712207 | |
| decrease toxicity | |
| An immune therapy, Rituximab, is widely used to treat cancer. It is associated with gut problems like mucositis. It is approved that dysbiosis of the gut microbiota has a link with the cause of mucositis. Rituximab reduces the abundance of Lactobacillus reuteri in the gut. The oral administration of Lactobacillus reuteri controls the inflammatory process caused by rituximab by regulating the T helper cells' level. |
Browse Drug-Microbiome Relationship
Home